Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by OrthoPediatrics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: OrthoPediatrics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 1:56 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001425450-26-000070
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 52,366 | 44,019 | 95,756 | 82,281 |
| Operating expenses: | ||||
| Sales and marketing | 21,294 | 19,103 | 39,764 | 35,675 |
| General and administrative | 32,814 | 30,443 | 63,837 | 60,723 |
| Restructuring | 1 | 2,971 | 1 | 3,011 |
| Research and development | 2,325 | 2,159 | 4,556 | 4,510 |
| Total operating expenses | 56,434 | 54,676 | 108,158 | 103,919 |
| Operating loss | (4,068) | (10,657) | (12,402) | (21,638) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is OrthoPediatrics's G&A?
- OrthoPediatrics (KIDS) reported G&A of $32.81M in Q2 2026.
- How has OrthoPediatrics's G&A changed year-over-year?
- OrthoPediatrics's G&A increased by 7.8% year-over-year, from $30.44M to $32.81M.
- What is the long-term trend for OrthoPediatrics's G&A?
- Over 4 years (2021 to 2025), OrthoPediatrics's G&A has grown at a 27.0% compound annual growth rate (CAGR), from $46.06M to $119.83M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about OrthoPediatrics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude